



an Open Access Journal by MDPI

Advances in Cancer Biology and Experimental Anticancer Therapies

Guest Editors:

Dr. Damian Gawel

1. Centre of Postgraduate
Medical Education, Department
of Immunohematology,
Marymoncka 99/103, 01-813
Warsaw, Poland

2. Centre of Postgraduate
Medical Education, Department
of Biochemistry and Molecular
Biology, Marymoncka 99/103, 01-
813 Warsaw, Poland

Dr. Tiziana Vavalà

AOU Città della Salute e della
Scienza, Torino, Italy

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editors

Dear Colleagues,

Cancer rates are on the rise. Among the various barriers to tumor treatment, the phenomenon of multidrug resistance (MDR) is a major obstacle limiting the effectiveness of the administered chemo drugs. Therefore, it is essential to intensify studies on the molecular mechanisms of carcinogenesis and develop novel tactics to predict, diagnose, and fight tumors. Currently, selective kinase inhibitors, micro-RNAs, nano-based theranostic tools, and combinatory approaches are considered the most promising strategies. This issue aims to provide an update on the currently investigated molecular factors promoting the progression of cancer and antitumor therapeutic strategies.

Dr. Damian Gawel

Dr. Tiziana Vavalà

Guest Editors



mdpi.com/si/109563

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI